Individualization of treatment in non-small cell lung cancer.
Two recently reported randomized studies discussed below are paving the way for personalized treatment approaches for patients with non-small cell lung cancer (NSCLC). Both studies show that accurate subclassification of NSCLC will become necessary to prescribe chemotherapy doublets and epidermal growth factor receptor tyrosine kinase inhibitors. It is expected that the practice of the last 30 years of lumping all NSCLC subtypes together will soon come to an end.
Bernie Banton Centre, University of Sydney Hospital Road, Concord, 2139 NSW Australia.
Nico
N
van Zandwijk